<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1407210864
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2009
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NEXAVAR 200 MG F-C TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SORAFENIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        7885.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BAYER  AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BAYER  AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAYER PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XE05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Nexavar is and what it is used for</strong></p><p>Nexavar is used to treat liver cancer (hepatocellular carcinoma).</p><p>Nexavar is also used to treat kidney cancer (advanced renal cell carcinoma) at an advanced stage when standard therapy has not helped to stop your disease or is considered unsuitable.</p><p>Nexavar is used to treat thyroid cancer (differentiated thyroid carcinoma).</p><p>Nexavar is a so-called multikinase inhibitor. It works by slowing down the rate of growth of cancer cells and cutting off the blood supply that keeps cancer cells growing.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Nexavar </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to sorafenib or any of the other ingredients of this medicine (listed in section 6).</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Nexavar.</p><p><strong>&nbsp;</strong></p><p><strong>Take special care with Nexavar</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you experience skin problems</strong>. Nexavar can cause rashes and skin reactions, especially on the hands and feet. These can usually be treated by your doctor. If not, your doctor may interrupt treatment or stop it altogether.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have high blood pressure.</strong> Nexavar can raise blood pressure, and your doctor will usually monitor your blood pressure and may give you a medicine to treat your high blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have or have had an aneurysm </strong>(enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have diabetes</strong>. Blood sugar levels in diabetic patients should be checked regularly in order to assess if anti-diabetic medicine&rsquo;s dosage needs to be adjusted to minimize the risk of low blood sugar.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you get any bleeding problems, or are taking warfarin or phenprocoumon</strong>. Treatment with Nexavar may lead to a higher risk of bleeding. If you are taking warfarin or phenprocoumon, medicines which thin the blood to prevent blood clots, there may be a greater risk of bleeding.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you get chest pain or heart problems</strong>. Your doctor may decide to interrupt treatment or stop it altogether.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have a heart disorder</strong>, such as an abnormal electrical signal called &laquo;prolongation of the QT interval&raquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are going to have surgery, or if you had an operation recently</strong>. Nexavar might affect the way your wounds heal. You will usually be taken off Nexavar if you are having an operation. Your doctor will decide when to start with Nexavar again.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are taking irinotecan or are given docetaxel</strong>, which are also medicines for cancer. Nexavar may increase the effects and, in particular, the side effects of these medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are taking Neomycin or other antibiotics.</strong> The effect of Nexavar may be decreased.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Liver problems</strong> (drug-induced hepatitis). Nexavar may cause liver problems that may lead to liver failure and death. Your doctor will do blood tests to check your liver function regularly during your treatment with Nexavar.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have severe liver impairment</strong>. You may experience more severe side effects when taking this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have poor kidney function</strong>. Your doctor will monitor your fluid and electrolyte balance.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Fertility</strong>. Nexavar may reduce fertility in both men and women. If you are concerned, talk to a doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Holes in the gut wall</strong> (gastrointestinal perforation) may occur during treatment (see section 4: Possible Side Effects). In this case your doctor will interrupt the treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have thyroid cancer</strong>. Your doctor will monitor blood calcium and thyroid hormone levels.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you experienced the following, contact your doctor immediately as this can be a life-threatening condition:</strong> nausea, shortness of breath, irregular heartbeat, muscular cramps, seizure, clouding of urine and tiredness. These may be caused by a group of metabolic complications that can occur during treatment of cancer that are caused by the break-down products of dying cancer cells (Tumour lysis syndrome (TLS)) and can lead to changes in kidney function and acute renal failure (see also section 4: Possible Side Effects).</p><p><strong>&nbsp;</strong></p><p><strong>Tell your doctor if any of these affect you. </strong>You may need treatment for them, or your doctor may decide to change your dose of Nexavar, or stop treatment altogether (see also section 4: Possible side effects).</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>Children and adolescents have not yet been tested with Nexavar.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Nexavar</strong></p><p>Some medicines may affect Nexavar, or be affected by it. Tell your doctor or pharmacist if you are taking, have recently taken or might take anything in this list or any other medicines, including medicines obtained without a prescription:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin, Neomycin or other medicines used to treat infections (<strong>antibiotics</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; St John&rsquo;s wort, a herbal treatment for <strong>depression</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Phenytoin, carbamazepine or phenobarbital, treatments for <strong>epilepsy</strong> and other conditions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Dexamethasone, a <strong>corticosteroid </strong>used for various conditions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Warfarin or phenprocoumon, anticoagulants used to <strong>prevent blood clots</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Doxorubicin, capecitabine, docetaxel, paclitaxel and irinotecan, which are <strong>cancer treatments</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Digoxin, a treatment for mild to <strong>moderate heart failure</strong></p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p><strong>Avoid becoming pregnant while being treated with Nexavar</strong>. If you could become pregnant use adequate contraception during treatment and for 6 months following the last dose of Nexavar. If you become pregnant while being treated with Nexavar, immediately tell your doctor who will decide if the treatment should be continued.</p><p><strong>You must not breast-feed your baby during Nexavar treatment</strong>, as this medicine may interfere with the growth and development of your baby.</p><p><strong>Males with female partners who can be pregnant or are pregnant</strong>. Use effective contraception during treatment with Nexavar and for 3 months following the last dose.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>There is no evidence that Nexavar will affect the ability to drive or to operate machines.</p><p><strong>&nbsp;</strong></p><p><strong>Nexavar contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &ldquo;sodium free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The recommended dose of Nexavar in adults is 2 x 200 mg tablets, twice daily.</strong></p><p>This is equivalent to a daily dose of 800 mg or four tablets a day.</p><p><strong>Swallow Nexavar tablets with a glass of water</strong>, either without food or with a low-fat or moderate fat meal. Do not take this medicine with high fat meals, as this may make Nexavar less effective. If you intend to have a high fat meal, take the tablets at least 1 hour before or 2 hours after the meal.</p><p>Always take this medicine exactly as your doctor has told you to. Check with your doctor or pharmacist if you are not sure.</p><p>Nexavar is a hazardous drug. Excercise caution when handling to minimize risk of exposure.</p><p>The tablets should not be broken or crushed.</p><p>It is important to take this medicine at about the same times each day, so that there is a steady amount in the bloodstream.</p><p>You will usually carry on taking this medicine as long as you are getting clinical benefits, and not suffering unacceptable side effects.</p><p><strong>&nbsp;</strong></p><p><strong>If you take more Nexavar than you should</strong></p><p><strong>Tell your doctor straight away</strong> if you (or anyone else) have taken more than your prescribed dose. Taking too much Nexavar makes side effects more likely or more severe, especially diarrhoea and skin reactions. Your doctor may tell you to stop taking this medicine.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take Nexavar</strong></p><p>If you have missed a dose, take it as soon as you remember. If it is nearly time for the next dose, forget about the missed one and carry on as normal. Do not take a double dose to make up for forgotten individual doses.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects although not everybody gets them. This medicine may also affect the results of some blood tests.</p><p><strong>&nbsp;</strong></p><p><strong>Very common:&nbsp; </strong>may affect more than 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak or tired (fatigue)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; pain (including mouth pain, abdominal pain, headache, bone pain, tumour pain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; hair loss (alopecia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; flushed or painful palms or soles (hand foot skin reaction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; itching or rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; throwing up (vomiting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; bleeding (including bleeding in the brain, gut wall and respiratory tract; haemorrhage)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure, or increases in blood pressure (hypertension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite (anorexia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; joint pain (arthralgia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; dry skin</p><p><strong>&nbsp;</strong></p><p><strong>Common:</strong> may affect up to 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; flu-like illness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; indigestion (dyspepsia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; difficulty swallowing (dysphagia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; inflamed or dry mouth, tongue pain (stomatitis and mucosal inflammation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; low calcium levels in the blood (hypocalcaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; low potassium levels in the blood (hypokalaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; low blood sugar level (hypoglycaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain (myalgia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; disturbed sensations in fingers and toes, including tingling or numbness (peripheral sensory neuropathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; erection problems (impotence)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; altered voice (dysphonia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; acne</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; inflamed, dry or scaly skin that sheds (dermatitis, skin desquamation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; heart failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; heart attack (myocardial infarction) or chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; tinnitus (ringing sound in the ear)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; kidney failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; abnormally high levels of protein in the urine (proteinuria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; general weakness or loss of strength (asthenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the number of white blood cells (leucopenia and neutropenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the number of red blood cells (anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; low number of platelets in the blood (thrombocytopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of hair follicles (folliculitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; underactive thyroid gland (hypothyroidism)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; low sodium levels in the blood (hyponatraemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; distortion of the sense of taste (dysgeusia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; red in the face and often other areas of the skin (flushing)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; runny nose (rhinorrhoea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; heartburn (gastro oesophageal reflux disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; skin cancer (keratoacanthomas/squamous cell cancer of the skin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; a thickening&nbsp; of the outer layer of the skin (hyperkeratosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; a sudden, involuntary contraction of a muscle (muscle spasms)</p><p>&nbsp;</p><p><strong>Uncommon: </strong>may affect up to 1 in 100 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; inflamed stomach lining (gastritis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; pain in the tummy (abdomen) caused by pancreatitis, inflammation of the gall bladder and/or bile ducts</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; yellow skin or eyes (jaundice) caused by high levels of bile pigments (hyperbilirubinaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; allergic like reactions (including skin reactions and hives)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; dehydration</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; enlarged breasts (gynaecomastia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; breathing difficulty (lung disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; eczema</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; overactive thyroid gland (hyperthyroidism)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; multiple skin eruptions (erythema multiforme)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; abnormally high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; holes in the gut wall (gastrointestinal perforation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; reversible swelling in the rear part of the brain that can be associated with headache, altered consciousness, fits and visual symptoms including visual loss (reversible posterior leukoencephalopathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; a sudden, severe allergic reaction (anaphylactic reaction)</p><p><strong>&nbsp;</strong></p><p><strong>Rare: </strong>may affect up to 1 in 1,000 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction with swelling of the skin (e. g. face, tongue) that may cause difficulty in breathing or swallowing (angioedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; abnormal heart rhythm (QT prolongation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver, which may lead to nausea, vomiting, abdominal pain, and jaundice (drug induced hepatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; a sunburn-like rash that may occur on skin that has previously been exposed to radiotherapy and can be severe (radiation recall dermatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; serious reactions of the skin and/or mucous membranes which may include painful blisters and fever, including extensive detachment of the skin (Stevens-Johnson syndrome and toxic epidermal necrolysis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; abnormal muscle breakdown which can lead to kidney problems (rhabdomyolysis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; damage of the kidney causing them to leak large amounts of protein (nephrotic syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the vessels in the skin which may result in rash (leucocytoclastic vasculitis)</p><p><strong>&nbsp;</strong></p><p><strong>Not known: </strong>frequency cannot be estimated from the available data</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; impaired brain function that can be associated with e.g. drowsiness, behavioural changes, or confusion (encephalopathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; an enlargement and weakening of a blood vessel wall or a tear in a blood vessel wall (aneurysms and artery dissections).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; jaw bone necrosis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; nausea, shortness of breath, irregular heartbeat, muscular cramps, seizure, clouding of urine and tiredness (Tumour lysis syndrome (TLS)) (see section 2).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; blood clots in small blood vessels (thrombotic microangiopathy)</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Reporting of side effects</u></strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>To report any side effect(s):</u></strong></p><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC).</p><p>SFDA call center: 19999.</p><p>Email: npc.drug@sfda.gov.sa.</p><p>Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>.&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>.&nbsp;&nbsp;&nbsp; <strong>Do not use this medicine after the expiry date</strong> which is stated on the carton and on each blister after EXP. The expiry date refers to the last day of that month.</p><p>.&nbsp;&nbsp;&nbsp; Do not store this medicine above 30&deg;C.</p><p>.&nbsp;&nbsp;&nbsp; NEXAVAR is a Hazardous drug; need caution when handling to minimize risk of exposure.</p><p>.&nbsp;&nbsp;&nbsp; Transport and store medicine in the original container or blister.</p><p>.&nbsp;&nbsp;&nbsp; Caution should be observed in handling broken or crushed tablets Avoid direct contact of the NEXAVAR with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, rinse eyes thoroughly with sterile water, or plain water if sterile water is unavailable.</p><p>.&nbsp;&nbsp;&nbsp; People who are not taking medication should not be exposed to it.</p><p>.&nbsp;&nbsp;&nbsp; Women who are pregnant or who may be pregnant should avoid exposure to NEXAVAR tablets.</p><p>.&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Nexavar contains</strong></p><p>The <strong>active </strong>substance is sorafenib. Each film-coated tablet contains 200 mg sorafenib (as tosylate).</p><p>The <strong>other ingredients</strong> are:</p><p><u>Tablet core:</u> croscarmellose sodium, microcrystalline cellulose, hypromellose, sodium laurilsulfate, magnesium stearate.</p><p><u>Tablet coating:</u> hypromellose, macrogol, titanium dioxide (E 171), ferric oxide red (E 172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Nexavar looks like and contents of the pack
Nexavar 200 mg film-coated tablets are red and round with the Bayer cross on one side and “200” on the other side. 
They come in packs of 60 tablets: six blister per pack, each blister contains 10 tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer and Marketing</strong><strong> </strong></p><p><strong>Authorisation Holder</strong><strong>:</strong></p><p>Bayer AG,</p><p>Kaiser-Wilhelm-Allee 1</p><p>51368 Leverkusen, Germany.</p><p>&nbsp;</p><p><strong>Secondary Packed by:</strong></p><p>DEEF Pharmaceutical Ind. Co.,</p><p>Saudi Arabia - Al Qassim</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in May 2022.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو نكسافار و لأي غرض يستخدم</strong></p><p dir="RTL">يستخدم نكسافار لعلاج سرطان الكبد<em> (سرطان خلايا الكبد)</em>.</p><p dir="RTL">يستخدم نكسافار أيضاًً لعلاج سرطان الكلى<em> (سرطان خلايا الكلى المتقدم)</em> في المرحلة المتقدمة من المرض عندما يكون العلاج القياسي غير مساعد في إيقاف المرض أو تم اعتباره غير مناسب.</p><p dir="RTL">و يستخدم نكسافار لعلاج سرطان الغدة الدرقية<em> (سرطان الغدة الدرقية المتباين)</em></p><p dir="RTL">نكسافار هو ما يسمى مثبط للعديد من الكيناز<em> (أنزيم مُخَمِّر)</em>. يعمل على إبطاء معدل النمو لخلايا السرطان ويقطع عنها إمداد الدم الذي يحافظ على نمو خلايا السرطان.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا تحتاج معرفته قبل تناول نكسافار</strong></p><p dir="RTL"><strong>لا تتناول نكسافار</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية للسورافينب أو لأي من المكونات الأخرى في هذا الدواء (المذكورة في الجزء 6).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحذيرات و احتياطات </strong></p><p dir="RTL">أبلغ طبيبك أو الصيدلي قبل تناول نكسافار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اتخذ عناية خاصة مع نكسافار</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني من مشاكل جلدية</strong>. يمكن أن يسبب نكسافار طفح و تفاعلات جلدية، خاصة على الأيدي و الأقدام. عادة يمكن لطبيبك علاج ذلك. إذا لم يمكن ذلك، يمكن للطبيب وقف العلاج مؤقتاً أو إيقافه تماماً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان لديك ضغط دم عالي</strong>. نكسافار يمكن أن يرفع ضغط الدم، وطبيبك سوف يراقب عادة ضغط الدم و يمكن أن يعطيك أدوية لعلاج ضغط الدم المرتفع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني أو عانيت سابقاً من تمدد الأوعية الدموية</strong> (تضخم وضعف جدار الأوعية الدموية) أو تمزق في جدار الأوعية الدموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت مصابًا بداء السكري</strong>. يجب فحص مستويات السكر في الدم في مرضى السكري بانتظام من أجل تقييم ما إذا كانت جرعة الدواء المضاد للسكري بحاجة إلى تعديل لتقليل خطر انخفاض نسبة السكر في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا أصبت بأية مشاكل نزفية، أو انك تستخدم وارفارين أو فينبروكومون</strong>. فإن العلاج بالنكسافار يمكن أن يؤدي إلى ارتفاع مخاطر النزيف. إذا كنت تستخدم ورفارين أو فينبروكومون، أدوية تمييع للدم (زيادة سيولة الدم) لمنع جلطات الدم، فهناك مخاطر أعلى للنزيف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان لديك ألم في الصدر أو مشاكل في القلب</strong>. يمكن للطبيب أن يقرر وقف العلاج مؤقتاً أو إيقافه تماماً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان لديك اضطراب للقلب</strong>، مثل إشارة كهربائية غير طبيعية و التي تسمى &laquo;إطالة فترة Q &ndash; T (في تخطيط كهربائية القلب)&raquo;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت سوف تجري عملية جراحية، أو قد أجريت لك جراحة حديثاً.</strong> يمكن أن يؤثر نكسافار في عملية التئام الجروح. عادة ستتوقف عن تناول نكسافار إذا كنت سوف تجري عملية جراحية. سوف يحدد طبيبك متى ستبدأ تناول نكسافار مرة أخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تستخدم إيرينوتيكان أو يعطى لك دوسيتاكسل</strong>، و هما أيضاً أدوية لعلاج السرطان. يمكن لنكسافار أن يزيد من تأثيرهما، و خاصة، التأثيرات الجانبية لهذه الأدوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تستخدم نيوميسين أو مضادات حيوية أخرى</strong>. تأثير النكسافار يمكن أن يقل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل الكبد</strong> (التهاب الكبد الناجم عن الدواء). قد يسبب نكسافار مشاكل في الكبد قد تؤدي إلى فشل الكبد والوفاة. سيقوم طبيبك بإجراء فحوصات الدم لفحص وظائف الكبد بانتظام أثناء علاجك باستخدام نكسافار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان لديك خلل شديد في الكبد.</strong> يمكن أن تعاني المزيد من الآثار الجانبية الشديدة عندما تستخدم هذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان لديك نقص في وظيفة الكلى</strong>. طبيبك سوف يراقب توازن السوائل و الشوارد الكهربائية لديك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الخصوبة</strong>. يمكن لنكسافار أن يقلل الخصوبة لدى الرجل و المرأة. إذا كنت مهتماً تحدث مع الطبيب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ثقوب في جدار الأمعاء</strong> (ثقب معدى معوي) يمكن حدوثه أثناء العلاج (أنظر جزء 4: الآثار الجانبية المحتملة). في هذه الحالة سوف يقطع (يوقف) الطبيب العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان لديك سرطان الغدة الدرقية</strong>. طبيبك سوف يراقب مستوى الكالسيوم في الدم ومستويات هرمون الغدة الدرقية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا واجهت ما يلي، فاتصل بطبيبك على الفور حيث يمكن أن تكون حالة مهددة للحياة:</strong> غثيان، ضيق في التنفس، عدم انتظام ضربات القلب، تشنجات عضلية، نوبة، ضبابية البول (بول غير صاف) و إرهاق. قد تكون ناجمة عن مجموعة من المضاعفات الأيضية التي يمكن أن تحدث أثناء علاج السرطان والتي تسببها نواتج تحلل الخلايا السرطانية المحتضرة (متلازمة تحلل الورم (TLS)) ويمكن أن تؤدي إلى تغيرات في وظائف الكلى والفشل الكلوي الحاد (انظر أيضًا القسم 4: الآثار الجانبية المحتملة).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>اخطر طبيبك لو أي من هذا يؤثر عليك</strong>. قد تحتاج للعلاج منهم، أو طبيبك سوف يقرر تغيير جرعة نكسافار، أو إيقاف العلاج تماماً. (أنظر أيضاً الجزء 4: الآثار الجانبية المحتملة)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال و المراهقين:</strong></p><p dir="RTL">حتى الآن لم يتم اختبار نكسافار مع الأطفال والمراهقين .</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناول أدوية أخرى مع نكسافار </strong></p><p dir="RTL">بعض الأدوية يمكن أن تؤثر على نكسافار أو تتأثر به. أبلغ طبيبك أو الصيدلي إذا كنت تتناول، تناولت حديثاً أو يمكن أن تتناول أي أدوية مذكورة في هذه القائمة أو أي أدوية أخرى، تشمل الأدوية التي يتم الحصول عليها بدون وصفة طبية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين، نيوميسين أو أدوية أخرى يتم تناولها للعلاج من العدوى (<strong>مضادات حيوية</strong>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; عشب القديس جون (عشب سانت جون)، علاج عشبي <strong>للاكتئاب</strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين، كاربامازبين أو فينوباربيتال، أدوية لعلاج <strong>الصرع </strong>ولحالات أخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; دكساميتازون، <strong>ستيرويد قشري</strong> يستخدم لحالات مختلفة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ورفارين أو فينبروكومون، مضادات التجلط تستخدم <strong>لمنع جلطات الدم</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ديكسوروبيسين، كابسيتابين، دوسيتاكسيل، باكليتاكسيل و ايرينوتيكان وهي أدوية أخرى <strong>لعلاج السرطان</strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسين علاج <strong>لقُصور القلب المعتدل أو المتوسط</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل و الرضاعة</strong></p><p dir="RTL"><strong>يجب تجنب الحمل أثناء العلاج بالنكسافار</strong>. إذا كان من الممكن أن يحدث حمل يجب استخدام وسيلة كافية لمنع الحمل أثناء العلاج ولمدة 6 أشهر بعد آخر جرعة من النكسافار . إذا حدث الحمل أثناء العلاج بالنكسافار، يجب تبليغ الطبيب فوراً و الذي سوف يقرر إذا كان العلاج يجب أن يستمر.</p><p dir="RTL"><strong>يجب عدم إرضاع طفلك من الثدي أثناء العلاج بالنكسافار</strong>، لأن هذا الدواء يمكن أن يتعارض مع نمو و تطور الطفل.</p><p dir="RTL"><strong>الذكور الذين لديهم شريكات يمكن أن تحملن أو حوامل</strong>. استخدم وسائل منع حمل فعالة أثناء العلاج بـالنكسافار ولمدة 3 أشهر بعد آخر جرعة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة و استخدام الماكينات</strong></p><p dir="RTL">لا يوجد دليل أن نكسافار سوف يؤثر على القدرة على القيادة أو تشغيل الماكينات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يحتوي نكسافار على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 مجم) لكل جرعة ، وهذا يعني بشكل أساسي &laquo;خالٍ من الصوديوم&raquo;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>جرعة نكسافار الموصى بها للبالغين هي 2 </strong><strong>x</strong><strong> قرص&nbsp; 200 مجم، مرتين يومياً.</strong></p><p dir="RTL">هذا يكافئ 800 مجم أو أربعة أقراص في اليوم .</p><p dir="RTL"><strong>يتم بَلع أقراص نكسافار مع كوب من الماء</strong>، إما بدون طعام أو مع وجبة قليلة-الدهن أو وجبة متوسطة الدهن. لا تستخدم هذا الدواء مع وجبات عالية الدهن، لأن ذلك يمكن أن يسبب انخفاض لفاعلية نكسافار. إذا كنت ترغب في الحصول على وجبة عالية الدهن أستخدم الأقراص ساعة واحدة على الأقل قبل الأكل أو بعد ساعتين من الأكل.</p><p dir="RTL">دائماً تناول هذا الدواء تماماً كما يقرره لك طبيبك. راجع طبيبك أو الصيدلاني إذا كنت غير متأكد.</p><p dir="RTL">نكسافار دواء خطر. توخي الحذر عند التعامل لتقليل مخاطر التعرض.</p><p dir="RTL">يجب عدم تكسير الأقراص أو سحقها.</p><p dir="RTL">من المهم تناول هذا الدواء&nbsp; يومياً في نفس المواعيد تقريباً، فبالتالي تتواجد كمية ثابتة في مجرى الدم.</p><p dir="RTL">سوف تستمر في تناول هذا الدواء كالمعتاد طالما أنك تحصل على فوائد إكلينيكية (سريرية)، و لا تعاني من آثار جانبية غير محتملة</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا تناولت نكسافار أكثر مما يجب</strong></p><p dir="RTL"><strong>ابلغ طبيبك فوراً</strong> إذا كنت قد تناولت (أو أي شخص آخر) أكثر من الجرعة الموصوفة. استخدام نكسافار أكثر مما ينبغي يجعل الآثار الجانبية أكثر حدوثاً أو أكثر خطورة، خاصة الإسهال و التفاعلات الجلدية. يمكن لطبيبك أن يخبرك بأن تتوقف عن تناول هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت أن تتناول نكسافار</strong></p><p dir="RTL">إذا نسيت جرعة، خذها حالما تذكرت. إذا كان ذلك قريب من الجرعة التالية، تغاضى عن الجرعة المنسية و استمر كالمعتاد. لا تأخذ جرعة مضاعفة لتعويض الجرعات الفردية المنسية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الآثار الجانبية المحتملة</strong></p><p dir="RTL">مثل كل الأدوية يمكن أن يسبب هذا الدواء آثار جانبية، لكن ليس كل شخص يصاب بها.</p><p dir="RTL">هذا الدواء يمكن أن يكون له أيضاً تأثير على نتائج بعض اختبارات الدم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة جداً</strong>: يمكن أن تصيب أكثر من 1 من كل 10 مستخدمين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إحساس بالغثيان (غثيان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إحساس بالضعف أو بالتعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم (يتضمن ألم في الفم، ألم البطن، صداع، ألم في العظم، ألم الورم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; احمرار أو ألم لراحة الأيدي (الكف) أو لأخمص الأقدام (متلازمة اليد و القدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حكة أو طفح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; قيئ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; نزف (يشمل النزف داخل المخ، جدار الأمعاء و الجهاز التنفسي؛ نزف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم، أو زيادة في ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; عدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; فقدان للشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم مفصلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; جلد جاف</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة</strong>: يمكن أن تصيب حتى 1 من 10 أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مرض يشبه الأنفلونزا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في البلع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الفم أو جفاف الفم، ألم في اللسان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مستويات منخفضة للكالسيوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مستويات منخفضة للبوتاسيوم في الدم (نقص بوتاسيوم الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى السكر في الدم (نقص سكر الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب حسي في أصابع اليد و أصابع القدم، يتضمن إحساس بوخز خفيف أو خدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الانتصاب (عجز جنسي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تغير الصوت</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حب الشباب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; جلد ملتهب، جلد متقشر متساقط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; قصور (فشل) فى القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية (احتشاء عضلة القلب) أو ألم في الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; طنين (صوت رنين في الأذن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; فشل كلوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مستويات عالية بصورة غير طبيعية للبروتين في البول (بروتينية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ضعف عام أو فقدان القوة (وهن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; النقص في عدد خلايا الدم البيضاء (نقص الكريات البيض والعدلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; النقص في عدد خلايا الدم الحمراء ( فقر الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية في الدم ( الصفيحات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بصيلات الشعر (الجريبات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; قصور الغدة الدرقية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصوديوم في الدم (نقص صوديوم الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; خلل فى حاسة التذوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; أحمرارفي الوجه ومناطق أخرى من الجلد في كثير من الأحيان&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; سيلان الأنف (rhinorrhoea)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حرقة في المعدة (ارتجاع المرئ المعدي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الجلد (keratoacanthomas&nbsp; /&nbsp; سرطان الخلايا الحرشفية للجلد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; سماكة الطبقة الخارجية من الجلد&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تقلص فجائي لا إرادي في العضلات (تشنجات العضلات)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير شائعة</strong>: يمكن أن تصيب حتى 1 من 100 شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بطانة المعدة (التهاب المعدة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن بسبب التهاب البنكرياس، التهاب المرارة و / أو قنوات الصفراء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد أو العينين (يرقان) بسبب ارتفاع مستوى أصباغ الصفراء (ارتفاع البيلروبين في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات شبيهة بتفاعلات الحساسية (تتضمن تفاعلات جلدية و شرى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; جفاف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الثديين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس (مرض في الرئة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إكزيما</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; نشاط الغدة الدرقية أكثر من الطبيعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي متعدد (حُمامَى عَديدَةُ الأَشْكال)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ضغط دم عالي غير طبيعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ثقوب في جدار الأمعاء (ثقب معدي معوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تورم مرتد في الجزء الخلفي من المخ الذي يمكن أن يكون مصحوب بصداع، تغير بالوعي، تشنج و أعراض إبصارية تتضمن فقدان الإبصار (اعتلال بيضاء الدماغ الخلفي قابلة للعكس (تعود لحالتها السابقة))</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي شديد فجائي</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة:</strong> يمكن أن تصيب حتى 1 من 1000 شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية مع انتفاخ الجلد (مثل الوجه، اللسان) الذي قد يسبب صعوبة في التنفس أو البلع (وذمة وعائية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; نظم غير طبيعية للقلب (إطالة فترة Q &ndash; T (في تخطيط كهربائية القلب))</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في الكبد، الذي قد يؤدي إلى غثيان، قيء، ألم في البطن، و مرض اليرقان (التهاب الكبد المسبب بدواء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الجلد الذي سبق تعرضه للعلاج بالأشعة يمكن أن يحدث عليه طفح جلدي يشبه حروق الشمس و يمكن أن يكون شديد (التهاب جلدي استذكاري للإشعاع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات خطيرة في الجلد و / أو الأغشية المخاطية التي قد تشتمل على حويصلات مؤلمة و حمى، بما في ذلك انفصال لمساحات واسعة من الجلد (متلازمة ستيفن جونسون و الانحلال النخري السام للبشرة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اعتلال غير طبيعي للعضلات الذي يمكن أن يؤدي إلى مشاكل في الكلى (انحلال العضلات المخططة rhabdomyolysis)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تلف في الكلى مما يسبب للكلى تسريب كميات كبيرة من البروتين (المتلازمة الكلوية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية في الجلد مما قد يؤدي إلى طفح جلدي (التهاب الأوعية الصغيرة في الجلد (leucocytoclastic vasculitis)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير معروفة: لا يمكن تقدير معدل حدوثها من البيانات المتوفرة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اختلال وظائف المخ التي يمكن أن يرافقها مثلا النعاس، التغيرات السلوكية، أو الارتباك (التهاب الدماغ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تضخم وضعف جدار الأوعية الدموية أو تمزق في جدار الأوعية الدموية (تمدد الأوعية الدموية وانسداد الشريان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تنخر عظم الفك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; غثيان، ضيق في التنفس، عدم انتظام ضربات القلب، تقلصات عضلية، نوبة صرع، ضبابية البول (بول غير صاف) و إرهاق (متلازمة انحلال الورم (TLS)) (انظر القسم 2).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; جلطات في الأوعية الدموية الصغيرة (اعتلال الأوعية الدقيقة التخثري)</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong><u>الإبلاغ عن الأعراض الجانبية</u></strong></p><p dir="RTL">إذا تم اصابتك بأي من الآثار الجانبية، ابلغ عنها طبيبك أو الصيدلي. هذا يشمل أي آثار جانبية محتملة غير مدونة في هذه النشرة. يمكن أن تساعد من خلال الإبلاغ عن الآثار الجانبية على توفير مزيد من المعلومات عن سلامة هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p dir="RTL"><strong>السعودية</strong><strong>:</strong></p><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز اتصال الهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الالكتروني: https://ade.sfda.gov.sa</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يتم تخزين نكسافار</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; احفظ الدواء بعيداً عن متناول و نظر الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تتناول هذا بعد تاريخ انتهاء الصلاحية المذكور</strong> علي العلبة الكرتونية و علي كل شريط بعد EXP . تاريخ انتهاء الصلاحية يشير إلى أخر يوم من ذلك الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ هذا الدواء في درجة حرارة لا تزيد عن 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; نكسافار عقار خطر. يجب توخي الحذر عند التعامل به لتقليل مخاطر التعرض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; قم بنقل الدواء وتخزينه في العبوة الأصلية أو شريط الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; يجب توخي الحذر عند التعامل مع الأقراص المكسورة أو المسحوقة. تجنب ملامسة نكسافار المباشرة للجلد أو الأغشية المخاطية. في حالة حدوث مثل هذا التلامس، اغسلها جيدًا بالماء والصابون، واشطف العين جيدًا بالماء المعقم، أو بالماء العادي إذا كان الماء المعقم غير متوفر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لا يجب أن يتعرض الأشخاص الذين لا يتناولون أدوية لها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; يجب على النساء الحوامل أو اللواتي قد يحملن، تجنب التعرض لأقراص نكسافار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لا يجب التخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي كيف تتخلص من الأدوية التي لم تعد في حاجة إليها. هذه الإجراءات سوف تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات العبوة و معلومات أخرى</strong></p><p dir="RTL"><strong>ما هي محتويات نكسافار</strong></p><p dir="RTL"><strong>المادة الفعالة</strong> هي سورافينب. يحتوي كل قرص مغلف على 200 مجم سورافينب (في شكل توزيلات).</p><p dir="RTL"><strong>المواد الأخرى</strong> هي:</p><p dir="RTL"><u>الجزء المركزى من القرص</u>: كروسكارميللوز صوديوم، سليلوز ذات بلورات مجهرية، هيبروميللوز، لوريلسلفات الصوديوم، ستيارات المغنيزيوم</p><p dir="RTL"><u>الطبقة الخارجية من القرص</u>: هيبروميللوز، ماكروغول (= غليكُول عَديدُ الإيثيلين)، ثنائي اكسيد التيتانيوم (E171)، أكسيد الحديديك الأحمر (E172)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو نكسافار و كيف تبدو محتويات العبوة</strong></p><p dir="RTL">نكسافار 200 مجم هي أقراص مغلفة لها لون أحمر و شكلها مستدير مع علامة باير علي الوجه الأول و &laquo;200&raquo; علي الوجه الآخر.</p><p dir="RTL">متوفر في عبوات بها 60 قرص: 6 شرائط في العبوة، كل شريط يحتوي على 10 أقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المصنع و حامل تصريح التسويق:</strong></p><p dir="RTL">باير ايه جي</p><p dir="RTL">قيصر-ويلهلم-آلي 1</p><p dir="RTL">51368 ليفركوزن، ألمانيا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التغليف الثانوي</strong><strong>:</strong></p><p dir="RTL">شركة ديف للصناعات الدوائية</p><p dir="RTL">المملكة العربية السعودية - القصيم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في مايو 2022.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nexavar 200 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 200 mg of sorafenib (as tosylate).

For the full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).

Red, round, biconvex film-coated tablets, debossed with Bayer cross on one side and "200" on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hepatocellular carcinoma</u></p><p><u>&nbsp;</u></p><p>Nexavar is indicated for the treatment of hepatocellular carcinoma (see section 5.1).</p><p>&nbsp;</p><p><u>Renal cell carcinoma</u></p><p>&nbsp;</p><p>Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.</p><p>&nbsp;</p><p><u>Differentiated thyroid carcinoma</u></p><p><u>&nbsp;</u></p><p>Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/H&uuml;rthle cell) thyroid carcinoma, refractory to radioactive iodine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nexavar treatment should be supervised by a physician experienced in the use of anticancer therapies.</p><p>&nbsp;</p><p><u>Posology</u></p><p><u>&nbsp;</u></p><p>The recommended dose of Nexavar<strong> </strong>in adults is 400&nbsp;mg sorafenib (two tablets of 200&nbsp;mg) twice daily (equivalent to a total daily dose of 800&nbsp;mg).</p><p>&nbsp;</p><p>Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.</p><p>&nbsp;</p><p>Nexavar is a hazardous drug. It is recommended to follow applicable special handling and disposal procedures (see Section 6.6)</p><p>&nbsp;</p><p>Tablets should be swallowed whole. They should not be broken or crushed</p><p>&nbsp;</p><p><u>Posology adjustments</u></p><p><u>&nbsp;</u></p><p>Management of suspected adverse drug reactions may require temporary interruption or dose reduction of sorafenib therapy.</p><p>&nbsp;</p><p>When dose reduction is necessary during the treatment of hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC), the Nexavar dose should be reduced to two tablets of 200&nbsp;mg sorafenib once daily (see section 4.4).</p><p>&nbsp;</p><p>When dose reduction is necessary during the treatment of differentiated thyroid carcinoma (DTC), the Nexavar dose should be reduced to 600&nbsp;mg sorafenib daily in divided doses (two tablets of 200&nbsp;mg and one tablet of 200&nbsp;mg twelve hours apart).</p><p>If additional dose reduction is necessary, Nexavar may be reduced to 400 mg sorafenib daily in divided doses (two tablets of 200 mg twelve hours apart), and if necessary further reduced to one tablet of 200 mg once daily. After improvement of non-haematological adverse reactions, the dose of Nexavar may be increased.</p><p>&nbsp;</p><p><em>Paediatric </em><em>population</em></p><p>The safety and efficacy of Nexavar in children and adolescents aged &lt; 18 years have not yet been established. No data are available.</p><p><em>&nbsp;</em></p><p><em>Elderly </em><em>population</em></p><p>No dose adjustment is required in the elderly (patients above 65 years of age).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is required in patients with mild, moderate or severe renal impairment. No data is available in patients requiring dialysis (see section 5.2).</p><p>&nbsp;</p><p>Monitoring of fluid balance and electrolytes in patients at risk of renal dysfunction is advised.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is required in patients with Child Pugh A or B (mild to moderate) hepatic impairment. No data is available on patients with Child Pugh C (severe) hepatic impairment (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>For oral use.</p><p>It is recommended that sorafenib should be administered without food or with a low or moderate fat meal. If the patient intends to have a high-fat meal, sorafenib tablets should be taken at least 1 hour before or 2 hours after the meal. The tablets should be swallowed with a glass of water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Dermatological toxicities</u></p><p><u>&nbsp;</u></p><p>Hand foot skin reaction (palmar-plantar erythrodysaesthesia) and rash represent the most common adverse drug reactions with sorafenib. Rash and hand foot skin reaction are usually CTC (Common Toxicity Criteria) Grade 1 and 2 and generally appear during the first six weeks of treatment with sorafenib. Management of dermatological toxicities may include topical therapies for symptomatic relief, temporary treatment interruption and/or dose modification of sorafenib, or in severe or persistent cases, permanent discontinuation of sorafenib (see section 4.8).</p><p>&nbsp;</p><p><u>Hypertension</u></p><p><u>&nbsp;</u></p><p>An increased incidence of arterial hypertension was observed in sorafenib-treated patients. Hypertension was usually mild to moderate, occurred early in the course of treatment, and was amenable to management with standard antihypertensive therapy. Blood pressure should be monitored regularly and treated, if required, in accordance with standard medical practice. In cases of severe or persistent hypertension, or hypertensive crisis despite institution of antihypertensive therapy, permanent discontinuation of sorafenib should be considered (see section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Aneurysms and artery dissections </u></p><p>&nbsp;</p><p>The use of VEGF pathway inhibitors in patients with or without hypertension may promote the formation of aneurysms and/or artery dissections. Before initiating Nexavar, this risk should be carefully considered in patients with risk factors such as hypertension or history of aneurysm.</p><p>&nbsp;</p><p><u>Hypoglycaemia</u></p><p>&nbsp;</p><p>Decreases in blood glucose, in some cases clinically symptomatic and requiring hospitalization due to loss of consciousness, have been reported during sorafenib treatment. In case of symptomatic hypoglycaemia, sorafenib should be temporarily interrupted. Blood glucose levels in diabetic patients should be checked regularly in order to assess if anti-diabetic medicinal product&#39;s dosage needs to be adjusted.</p><p>&nbsp;</p><p><u>Haemorrhage</u></p><p><u>&nbsp;</u></p><p>An increased risk of bleeding may occur following sorafenib administration. If any bleeding event necessitates medical intervention it is recommended that permanent discontinuation of sorafenib should be considered (see section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Cardiac ischaemia and/or infarction</u></p><p><u>&nbsp;</u></p><p>In a randomised, placebo-controlled, double-blind study (study 1, see section 5.1) the incidence of treatment-emergent cardiac ischaemia/infarction events was higher in the sorafenib group (4.9&nbsp;%) compared with the placebo group (0.4&nbsp;%). In study 3 (see section&nbsp;5.1) the incidence of treatment-emergent cardiac ischaemia/infarction events was 2.7&nbsp;% in sorafenib patients compared with 1.3&nbsp;% in the placebo group. Patients with unstable coronary artery disease or recent myocardial infarction were excluded from these studies. Temporary or permanent discontinuation of sorafenib should be considered in patients who develop cardiac ischaemia and/or infarction (see section&nbsp;4.8).</p><p>&nbsp;</p><p><u>QT interval prolongation</u><u> </u></p><p><u>&nbsp;</u></p><p>Sorafenib has been shown to prolong the QT/QTc interval (see section 5.1), which may lead to an increased risk for ventricular arrhythmias. Use sorafenib with caution in patients who have, or may develop prolongation of QTc, such as patients with a congenital long QT syndrome, patients treated with a high cumulative dose of anthracycline therapy, patients taking certain anti-arrhythmic medicines or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalaemia, hypocalcaemia, or hypomagnesaemia. When using sorafenib in these patients, periodic monitoring with on-treatment electrocardiograms and electrolytes (magnesium, potassium, calcium) should be considered.</p><p><em>&nbsp;</em></p><p><u>Gastrointestinal perforation</u></p><p><u>&nbsp;</u></p><p>Gastrointestinal perforation is an uncommon event and has been reported in less than 1% of patients taking sorafenib. In some cases this was not associated with apparent intra-abdominal tumour. Sorafenib therapy should be discontinued (see section 4.8).</p><p>&nbsp;</p><p><u>Tumour lysis syndrome (TLS)</u></p><p>&nbsp;</p><p>Cases of TLS, some fatal, have been reported in postmarketing surveillance in patients treated with sorafenib. Risk factors for TLS include high tumour burden, pre-existing chronic renal insufficiency, oliguria, dehydration, hypotension, and acidic urine. These patients should be monitored closely and treated promptly as clinically indicated, and prophylactic hydration should be considered.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p><u>&nbsp;</u></p><p>No data is available on patients with Child Pugh C (severe) hepatic impairment. Since sorafenib is mainly eliminated via the hepatic route exposure might be increased in patients with severe hepatic impairment (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><u>Warfarin co-administration</u></p><p><u>&nbsp;</u></p><p>Infrequent bleeding events or elevations in the International Normalised Ratio (INR) have been reported in some patients taking warfarin while on sorafenib therapy. Patients taking concomitant warfarin or phenprocoumon should be monitored regularly for changes in prothrombin time, INR or clinical bleeding episodes (see sections 4.5 and 4.8).</p><p>&nbsp;</p><p><u>Wound healing complications</u></p><p><u>&nbsp;</u></p><p>No formal studies of the effect of sorafenib on wound healing have been conducted. Temporary interruption of sorafenib therapy is recommended for precautionary reasons in patients undergoing major surgical procedures. There is limited clinical experience regarding the timing of reinitiation of therapy following major surgical intervention. Therefore, the decision to resume sorafenib therapy following a major surgical intervention should be based on clinical judgement of adequate wound healing.</p><p>&nbsp;</p><p><u>Elderly population</u></p><p><u>&nbsp;</u></p><p>Cases of renal failure have been reported. Monitoring of renal function should be considered.</p><p>&nbsp;</p><p><strong>Drug-Induced Liver Injury</strong></p><p>NEXAVAR -induced hepatitis is characterized by a hepatocellular pattern of liver damage with significant increases of transaminases which may result in hepatic failure and death. Increases in bilirubin and INR may also occur. The incidence of severe drug-induced liver injury, defined as elevated transaminase levels above 20 times the upper limit of normal or transaminase elevations with significant clinical sequelae (for example, elevated INR, ascites, fatal, or transplantation), was two of 3,357 patients (0.06%) in a global monotherapy database. Monitor liver function tests regularly. In case of significantly increased transaminases without alternative explanation, such as viral hepatitis or progressing underlying malignancy, discontinue NEXAVAR</p><p>&nbsp;</p><p><u>Drug-drug interactions</u></p><p><u>&nbsp;</u></p><p>Caution is recommended when administering sorafenib with compounds that are metabolised/eliminated predominantly by the UGT1A1 (e.g. irinotecan) or UGT1A9 pathways (see section 4.5).</p><p>&nbsp;</p><p>Caution is recommended when sorafenib is co-administered with docetaxel (see section 4.5).</p><p>&nbsp;</p><p>Co-administration of neomycin or other antibiotics that cause major ecological disturbances of the gastrointestinal microflora may lead to a decrease in sorafenib bioavailability (see section 4.5). The risk of reduced plasma concentrations of sorafenib should be considered before starting a treatment course with antibiotics.</p><p>&nbsp;</p><p>Higher mortality has been reported in patients with squamous cell carcinoma of the lung treated with sorafenib in combination with platinum-based chemotherapies. In two randomised trials investigating patients with Non-Small Cell Lung Cancer in the subgroup of patients with squamous cell carcinoma treated with sorafenib as add-on to paclitaxel/carboplatin, the HR for overall survival was found to be 1.81&nbsp;(95% CI 1.19; 2.74) and as add-on to gemcitabine/cisplatin 1.22 (95% CI 0.82; 1.80). No single cause of death dominated, but higher incidence of respiratory failure, hemorrhages and infectious adverse events were observed in patients treated with sorafenib as add-on to platinum-based chemotherapies.</p><p>&nbsp;</p><p><u>Disease specific warnings</u></p><p>&nbsp;</p><p><em><u>Differentiated thyroid cancer (DTC)</u></em></p><p><u>&nbsp;</u></p><p>Before initiating treatment, physicians are recommended to carefully evaluate the prognosis in the individual patient considering maximum lesion size (see section 5.1), symptoms related to the disease (see section 5.1) and progression rate.</p><p>&nbsp;</p><p>Management of suspected adverse drug reactions may require temporary interruption or dose reduction of sorafenib therapy. In study 5 (see section 5.1), 37% of subjects had dose interruption and 35% had dose reduction already in cycle 1 of sorafenib treatment.</p><p>&nbsp;</p><p>Dose reductions were only partially successful in alleviating adverse reactions. Therefore repeat evaluations of benefit and risk is recommended taking anti-tumour activity and tolerability into account.</p><p>&nbsp;</p><p><em>Haemorrhage in DTC</em></p><p>Due to the potential risk of bleeding, tracheal, bronchial, and oesophageal infiltration should be treated with localized therapy prior to administering sorafenib in patients with DTC.</p><p><em>&nbsp;</em></p><p><em>Hypocalcaemia in DTC </em></p><p>When using sorafenib in patients with DTC, close monitoring of blood calcium level is recommended. In clinical trials, hypocalcaemia was more frequent and more severe in patients with DTC, especially with a history of hypoparathyroidism, compared to patients with renal cell or hepatocellular carcinoma. Hypocalcaemia grade 3 and 4 occurred in 6.8% and 3.4% of sorafenib-treated patients with DTC (see section 4.8). Severe hypocalcaemia should be corrected to prevent complications such as QT-prolongation or torsade de pointes (see section QT prolongation).&nbsp;</p><p>&nbsp;</p><p><em>TSH suppression in DTC</em></p><p>In study 5 (see section 5.1), increases in TSH levels above 0.5mU/L were observed in sorafenib treated patients. When using sorafenib in DTC patients, close monitoring of TSH level is recommended.</p><p>&nbsp;</p><p><em><u>Renal cell carcinoma</u></em></p><p><u>&nbsp;</u></p><p>High Risk Patients, according to MSKCC (Memorial Sloan Kettering Cancer Center) prognostic group, were not included in the phase III clinical study in renal cell carcinoma (see study 1 in section 5.1), and benefit-risk in these patients has not been evaluated.</p><p><strong>&nbsp;</strong></p><p><u>Information about excipients</u></p><p><u>&nbsp;</u></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &ldquo;sodium free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Inducers of metabolic enzymes</u></p><p><u>&nbsp;</u></p><p>Administration of rifampicin for 5 days before administration of a single dose of sorafenib resulted in an average 37&nbsp;% reduction of sorafenib AUC. Other inducers of CYP3A4 activity and/or glucuronidation (e.g. Hypericum perforatum also known as St. John&rsquo;s wort, phenytoin, carbamazepine, phenobarbital, and dexamethasone) may also increase metabolism of sorafenib and thus decrease sorafenib concentrations.</p><p>&nbsp;</p><p><u>CYP3A4 inhibitors</u></p><p><u>&nbsp;</u></p><p>Ketoconazole, a potent inhibitor of CYP3A4, administered once daily for 7 days to healthy male volunteers did not alter the mean AUC of a single 50&nbsp;mg dose of sorafenib. These data suggest that clinical pharmacokinetic interactions of sorafenib with CYP3A4 inhibitors are unlikely.</p><p>&nbsp;</p><p><u>CYP2B6, CYP2C8 and CYP2C9 substrates</u></p><p><u>&nbsp;</u></p><p>Sorafenib inhibited CYP2B6, CYP2C8 and CYP2C9 <em>in vitro</em> with similar potency. However, in clinical pharmacokinetic studies, concomitant administration of sorafenib 400 mg twice daily with cyclophosphamide, a CYP2B6 substrate, or paclitaxel, a CYP2C8 substrate, did not result in a clinically meaningful inhibition. These data suggest that sorafenib at the recommended dose of 400&nbsp;mg twice daily may not be an <em>in vivo</em> inhibitor of CYP2B6 or CYP2C8.</p><p>Additionally, concomitant treatment with sorafenib and warfarin, a CYP2C9 substrate, did not result in changes in mean PT-INR compared to placebo. Thus, also the risk for a clinically relevant <em>in vivo</em> inhibition of CYP2C9 by sorafenib may be expected to be low. However, patients taking warfarin or phenprocoumon should have their INR checked regularly (see section 4.4).</p><p>&nbsp;</p><p><u>CYP3A4, CYP2D6 and CYP2C19 substrates</u></p><p><u>&nbsp;</u></p><p>Concomitant administration of sorafenib and midazolam, dextromethorphan or omeprazole, which are substrates for cytochromes CYP3A4, CYP2D6 and CYP2C19 respectively, did not alter the exposure of these agents. This indicates that sorafenib is neither an inhibitor nor an inducer of these cytochrome P450 isoenzymes. Therefore, clinical pharmacokinetic interactions of sorafenib with substrates of these enzymes are unlikely.</p><p>&nbsp;</p><p><u>UGT1A1 and UGT1A9 substrates</u></p><p><u>&nbsp;</u></p><p><em>In vitro</em>, sorafenib inhibited glucuronidation via UGT1A1 and UGT1A9. The clinical relevance of this finding is unknown (see below and section 4.4).</p><p>&nbsp;</p><p><em><u>In vitro</u></em><u> studies of CYP enzyme induction</u></p><p><u>&nbsp;</u></p><p>CYP1A2 and CYP3A4 activities were not altered after treatment of cultured human hepatocytes with sorafenib, indicating that sorafenib is unlikely to be an inducer of CYP1A2 and CYP3A4.</p><p>&nbsp;</p><p><u>P-gp-substrates</u></p><p><u>&nbsp;</u></p><p><em>In vitro</em>, sorafenib has been shown to inhibit the transport protein p-glycoprotein (P-gp). Increased plasma concentrations of P-gp substrates such as digoxin cannot be excluded with concomitant treatment with sorafenib.</p><p>&nbsp;</p><p><u>Combination with other anti-neoplastic agents</u></p><p><u>&nbsp;</u></p><p>In clinical studies sorafenib has been administered with a variety of other anti-neoplastic agents at their commonly used dosing regimens including gemcitabine, cisplatin, oxaliplatin, paclitaxel, carboplatin, capecitabine, doxorubicin, irinotecan, docetaxel and cyclophosphamide. Sorafenib had no clinically relevant effect on the pharmacokinetics of gemcitabine, cisplatin, carboplatin, oxaliplatin or cyclophosphamide.</p><p>&nbsp;</p><p><u>Paclitaxel/carboplatin</u></p><p><u>&nbsp;</u></p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administration of paclitaxel (225 mg/m<sup>2</sup>) and carboplatin (AUC = 6) with sorafenib (&le; 400 mg twice daily), administered with a 3-day break in sorafenib dosing (two days prior to and on the day of paclitaxel/carboplatin administration), resulted in no significant effect on the pharmacokinetics of paclitaxel.</p><p>&nbsp;</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Co-administration of paclitaxel (225 mg/m<sup>2</sup>, once every 3 weeks) and carboplatin (AUC=6) with sorafenib (400 mg twice daily, without a break in sorafenib dosing) resulted in a 47% increase in sorafenib exposure, a 29% increase in paclitaxel exposure and a 50% increase in 6-OH paclitaxel exposure. The pharmacokinetics of carboplatin were unaffected.</p><p>&nbsp;</p><p>These data indicate no need for dose adjustments when paclitaxel and carboplatin are co-administered with sorafenib with a 3-day break in sorafenib dosing (two days prior to and on the day of paclitaxel/carboplatin administration). The clinical significance of the increases in sorafenib and paclitaxel exposure, upon co-administration of sorafenib without a break in dosing, is unknown.</p><p>&nbsp;</p><p><u>Capecitabine</u></p><p><u>&nbsp;</u></p><p>Co-administration of capecitabine (750-1050 mg/m<sup>2</sup> twice daily, Days 1-14 every 21 days) and sorafenib (200 or 400&nbsp;mg twice daily, continuous uninterrupted administration) resulted in no significant change in sorafenib exposure, but a 15-50% increase in capecitabine exposure and a 0-52% increase in 5-FU exposure. The clinical significance of these small to modest increases in capecitabine and 5-FU exposure when co-administered with sorafenib is unknown.</p><p><em>&nbsp;</em></p><p><u>Doxorubicin/Irinotecan</u></p><p><u>&nbsp;</u></p><p>Concomitant treatment with sorafenib resulted in a 21&nbsp;% increase in the AUC of doxorubicin. When administered with irinotecan, whose active metabolite SN-38 is further metabolised by the UGT1A1 pathway, there was a 67&nbsp;-&nbsp;120&nbsp;% increase in the AUC of SN-38 and a 26&nbsp;-&nbsp;42&nbsp;% increase in the AUC of irinotecan. The clinical significance of these findings is unknown (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Docetaxel</u></p><p><u>&nbsp;</u></p><p>Docetaxel (75 or 100&nbsp;mg/m<sup>2</sup> administered once every 21 days) when co-administered with sorafenib (200 mg twice daily or 400 mg twice daily administered on Days 2 through 19 of a 21-day cycle with a 3-day break in dosing around administration of docetaxel) resulted in a 36-80&nbsp;% increase in docetaxel AUC and a 16-32&nbsp;% increase in docetaxel C<sub>max</sub>. Caution is recommended when sorafenib is co-administered with docetaxel (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Combination with other agents</u></p><p>&nbsp;</p><p><em>Neomycin</em></p><p>Co-administration of neomycin, a non-systemic antimicrobial agent used to eradicate gastrointestinal flora, interferes with the enterohepatic recycling of sorafenib (see section 5.2, Metabolism and Elimination), resulting in decreased sorafenib exposure. In healthy volunteers treated with a 5-day regimen of neomycin the average exposure to sorafenib decreased by 54%. Effects of other antibiotics have not been studied, but will likely depend on their ability to interfere with microorganisms with glucuronidase activity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p>There are no data on the use of sorafenib in pregnant women. Studies in animals have shown reproductive toxicity including malformations (see section 5.3). In rats, sorafenib and its metabolites were demonstrated to cross the placenta and sorafenib is anticipated to cause harmful effects on the foetus. Sorafenib should not be used during pregnancy unless clearly necessary, after careful consideration of the needs of the mother and the risk to the foetus.</p><p>&nbsp;</p><p><u>Lactation</u></p><p><u>&nbsp;</u></p><p>It is not known whether sorafenib is excreted in human milk. In animals, sorafenib and/or its metabolites were excreted in milk. Because sorafenib could harm infant growth and development (see section&nbsp;5.3), women must not breast-feed during sorafenib treatment.</p><p>&nbsp;</p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>Results from animal studies further indicate that sorafenib can impair male and female fertility (see section&nbsp;5.3).</p><p>&nbsp;</p><p><u>Women of childbearing potential/Contraception in males and females </u></p><p><em>Female </em></p><p>Advise females of reproductive potential to use effective contraception during treatment and for 6 months following the last dose of NEXAVAR.</p><p><em>Male </em></p><p>Based on genotoxicity and findings in animal reproduction studies, advise males with female partners of reproductive potential and pregnant partners to use effective contraception during treatment with NEXAVAR and for 3 months following the last dose of NEXAVAR</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. There is no evidence that sorafenib affects the ability to drive or to operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most important serious adverse reactions were myocardial infarction/ischaemia, gastrointestinal perforation, drug induced hepatitis, haemorrhage, and hypertension/hypertensive crisis.</p><p>&nbsp;</p><p>The most common adverse reactions were diarrhoea, fatigue, alopecia, infection, hand foot skin reaction (corresponds to palmar plantar erythrodysaesthesia syndrome in MedDRA) and rash.</p><p>&nbsp;</p><p>Adverse reactions reported in multiple clinical trials or through post-marketing use are listed below in table 1, by system organ class (in MedDRA) and frequency. Frequencies are defined as: very common (&ge;1/10), common (&ge;1/100&nbsp;to&nbsp;&lt;1/10), uncommon (&ge;1/1,000&nbsp;to&nbsp;&lt;1/100), rare (&sup3;1/10,000&nbsp;to&nbsp;&lt;1/1,000), not known (cannot be estimated from the available data).<em> </em></p><p>&nbsp;</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 1: All adverse reactions reported in patients in multiple clinical trials or through post-marketing use</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:101%"><thead><tr><td style="vertical-align:top"><p>System organ class</p></td><td style="vertical-align:top"><p>Very common<br />&nbsp;</p></td><td style="vertical-align:top"><p>Common<br />&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon<br />&nbsp;</p></td><td style="vertical-align:top"><p>Rare<br />&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>infection</p></td><td style="vertical-align:top"><p>folliculitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>lymphopenia</p></td><td style="vertical-align:top"><p>leucopenia</p><p>neutropenia</p><p>anaemia</p><p>thrombocytope&shy;nia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombotic microangiopathy</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypersensiti&shy;vity reactions (including skin reactions and urticaria)</p><p>anaphylactic reaction</p></td><td style="vertical-align:top"><p>angioedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypothyroidism</p></td><td style="vertical-align:top"><p>hyperthyroidism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>anorexia</p><p>hypo-phosphataemia</p></td><td style="vertical-align:top"><p>hypocalcaemia</p><p>hypokalaemia</p><p>hyponatraemia</p><p>hypoglycaemia</p></td><td style="vertical-align:top"><p>dehydration</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>tumour lysis syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>depression</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>peripheral sensory neuropathy</p><p>dysgeusia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>reversible posterior leukoencephalo-pathy*</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>encephalo&shy;pathy&deg;</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>congestive heart failure*</p><p>myocardial ischaemia and infarction*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>QT prolongation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>haemorrhage (inc. gastrointestinal*, respiratory tract* and cerebral haemorrhage*)</p><p>hypertension</p></td><td style="vertical-align:top"><p>flushing</p></td><td style="vertical-align:top"><p>hypertensive crisis*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>aneurysms and artery dissections</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>rhinorrhoea</p><p>dysphonia</p></td><td style="vertical-align:top"><p>interstitial lung disease-like events* (pneumonitis, radiation pneumonitis, acute respiratory distress, etc. )</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastro-intestinal disorders</p></td><td style="vertical-align:top"><p>diarrhoea</p><p>nausea</p><p>vomiting</p><p>constipation</p></td><td style="vertical-align:top"><p>stomatitis (including dry mouth and glossodynia)</p><p>dyspepsia</p><p>dysphagia</p><p>gastro oesophageal reflux disease</p></td><td style="vertical-align:top"><p>pancreatitis</p><p>gastritis</p><p>gastrointestinal perforations*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobi&shy;liary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>increase in bilirubin and jaundice, cholecystitis, cholangitis</p></td><td style="vertical-align:top"><p>drug induced hepatitis*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcuta&shy;neous tissue disorders</p></td><td style="vertical-align:top"><p>dry skin</p><p>rash</p><p>alopecia</p><p>hand foot skin reaction**</p><p>erythema</p><p>pruritus</p></td><td style="vertical-align:top"><p>keratoacan&shy;thoma/ squamous cell cancer of the skin</p><p>dermatitis exfoliative</p><p>acne</p><p>skin desquamation</p><p>hyperkeratosis</p></td><td style="vertical-align:top"><p>eczema</p><p>erythema multiforme</p></td><td style="vertical-align:top"><p>radiation recall dermatitis</p><p>Stevens-Johnson syndrome</p><p>leucocyto&shy;clastic vasculitis</p><p>toxic epidermal necrolysis*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculo-skeletal and connec&shy;tive tissue disorders</p></td><td style="vertical-align:top"><p>arthralgia</p></td><td style="vertical-align:top"><p>myalgia</p><p>muscle spasms</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>rhabdomyolysis</p></td><td style="vertical-align:top"><p>osteonecrosis of the jaw</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>renal failure</p><p>proteinuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>nephrotic syndrome</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>erectile dysfunction</p></td><td style="vertical-align:top"><p>gynaecomastia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and adminis&shy;tration site conditions</p></td><td style="vertical-align:top"><p>fatigue</p><p>pain (including mouth, abdominal, bone, tumour pain and headache)</p><p>fever</p></td><td style="vertical-align:top"><p>asthenia</p><p>influenza like illness</p><p>mucosal inflammation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investiga&shy;tions</p></td><td style="vertical-align:top"><p>weight decreased</p><p>increased amylase</p><p>increased lipase</p></td><td style="vertical-align:top"><p>transient increase in transaminases</p></td><td style="vertical-align:top"><p>transient increase in blood alkaline phosphatase</p><p>INR abnormal, prothrombin level abnormal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The adverse reactions may have a life-threatening or fatal outcome. Such events are either uncommon or less frequent than uncommon.</p><p>** &nbsp;&nbsp;&nbsp;&nbsp; Hand foot skin reaction corresponds to palmar plantar erythrodysaesthesia syndrome in MedDRA.</p><p>&deg; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cases have been reported in the post marketing setting.</p><p>&nbsp;</p><p><u>Further information on selected adverse drug reactions</u></p><p>&nbsp;</p><p><em>Congestive heart failure</em></p><p>In company sponsored clinical trials congestive heart failure was reported as an adverse event in 1.9% of patients treated with sorafenib (N= 2276). In study 11213 (RCC) adverse events consistent with congestive heart failure were reported in 1.7% of patients treated with sorafenib and 0.7% receiving placebo. In study 100554 (HCC), 0.99% of those treated with sorafenib and 1.1% receiving placebo were reported with these events.</p><p>&nbsp;</p><p><em>Additional information on special populations</em></p><p>In clinical trials, certain adverse drug reactions such as hand foot skin reaction, diarrhoea, alopecia, weight decrease, hypertension, hypocalcaemia, and keratoacanthoma/squamous cell carcinoma of skin occurred at a substantially higher frequency in patients with differentiated thyroid compared to patients in the renal cell or hepatocellular carcinoma studies.</p><p>&nbsp;</p><p><u>Laboratory test abnormalities in HCC (study 3) and RCC (study 1) patients</u></p><p><u>&nbsp;</u></p><p>Increased lipase and amylase were very commonly reported. CTCAE Grade 3 or 4 lipase elevations occurred in 11&nbsp;% and 9&nbsp;% of patients in the sorafenib group in study&nbsp;1 (RCC) and study 3 (HCC), respectively, compared to 7&nbsp;% and 9&nbsp;% of patients in the placebo group. CTCAE Grade 3 or 4 amylase elevations were reported in 1&nbsp;% and 2&nbsp;% of patients in the sorafenib group in study&nbsp;1 and study&nbsp;3, respectively, compared to 3&nbsp;% of patients in each placebo group. Clinical pancreatitis was reported in 2 of 451 sorafenib treated patients (CTCAE Grade&nbsp;4) in study&nbsp;1, 1 of 297 sorafenib treated patients in study&nbsp;3 (CTCAE&nbsp;Grade&nbsp;2), and 1 of 451 patients (CTCAE Grade&nbsp;2) in the placebo group in study&nbsp;1.</p><p>&nbsp;</p><p>Hypophosphataemia was a very common laboratory finding, observed in 45&nbsp;% and 35&nbsp;% of sorafenib treated patients compared to 12&nbsp;% and 11&nbsp;% of placebo patients in study&nbsp;1 and study&nbsp;3, respectively. CTCAE Grade 3 hypophosphataemia (1&nbsp;&ndash;&nbsp;2&nbsp;mg/dl) in study 1 occurred in 13&nbsp;% of sorafenib treated patients and 3&nbsp;% of patients in the placebo group, in study 3 in 11&nbsp;% of sorafenib treated patients and 2&nbsp;% of patients in the placebo group. There were no cases of CTCAE Grade 4 hypophosphataemia (&lt;&nbsp;1&nbsp;mg/dl) reported in either sorafenib or placebo patients in study 1, and 1 case in the placebo group in study 3. The aetiology of hypophosphataemia associated with sorafenib is not known.</p><p>&nbsp;</p><p>CTCAE Grade&nbsp;3 or 4 laboratory abnormalities occurring in &ge;&nbsp;5&nbsp;% of sorafenib treated patients included lymphopenia and neutropenia.</p><p>&nbsp;</p><p>Hypocalcaemia was reported in 12% and 26.5% of sorafenib treated patients compared to 7.5% and 14.8% of placebo patients in study 1 and study 3, respectively. Most reports of hypocalcaemia were low grade (CTCAE Grade 1 and 2). CTCAE grade 3 hypocalcaemia (6.0 &ndash; 7.0 mg /dL) occurred in 1.1% and 1.8% of sorafenib treated patients and 0.2% and 1.1% of patients in the placebo group, and CTCAE grade 4 hypocalcaemia (&lt; 6.0 mg/dL) occurred in 1.1% and 0.4% of sorafenib treated patients and 0.5% and 0% of patients in the placebo group in study 1 and 3, respectively. The aetiology of hypocalcaemia associated with sorafenib is not known.</p><p>&nbsp;</p><p>In studies 1 and 3 decreased potassium was observed in 5.4% and 9.5% of sorafenib-treated patients compared to 0.7% and 5.9% of placebo patients, respectively. Most reports of hypokalaemia were low grade (CTCAE Grade 1). In these studies CTCAE Grade 3 hypokalaemia occurred in 1.1% and 0.4% of sorafenib treated patients and 0.2% and 0.7% of patients in the placebo group. There were no reports of hypokalaemia CTCAE grade 4.</p><p>&nbsp;</p><p><u>Laboratory test abnormalities in DTC patients (study 5)</u></p><p><u>&nbsp;</u></p><p>Hypocalcaemia was reported in 35.7% of sorafenib treated patients compared to 11.0% of placebo patients. Most reports of hypocalcaemia were low grade. CTCAE grade 3 hypocalcaemia occurred in 6.8% of sorafenib treated patients and 1.9% of patients in the placebo group, and CTCAE grade 4 hypocalcaemia occurred in 3.4% of sorafenib treated patients and 1.0% of patients in the placebo group.</p><p>&nbsp;</p><p>Other clinically relevant laboratory abnormalities observed in the study 5 are shown in table 2.</p><p>&nbsp;</p><p><strong>Table 2: Treatment-emergent laboratory test abnormalities reported in DTC &nbsp;patient (study 5) double blind period</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:567px"><thead><tr><td rowspan="2"><p>Laboratory parameter,<br />(in % of samples investigated)</p></td><td colspan="3"><p>Sorafenib N=207</p></td><td colspan="8"><p>Placebo N=209</p></td></tr><tr><td><p>All Grades*</p></td><td><p>Grade 3*</p></td><td><p>Grade 4*</p></td><td><p>All Grades*</p></td><td colspan="4"><p>Grade 3*</p></td><td colspan="3"><p>Grade 4*</p></td></tr></thead><tbody><tr><td colspan="12"><p>Blood and lymphatic system disorders</p></td></tr><tr><td style="vertical-align:top"><p>Anemia</p></td><td><p>30.9</p></td><td><p>0.5</p></td><td><p>0</p></td><td><p>23.4</p></td><td colspan="6"><p>0.5</p></td><td><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td><p>18.4</p></td><td><p>0</p></td><td><p>0</p></td><td><p>9.6</p></td><td colspan="6"><p>0</p></td><td><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia</p></td><td><p>19.8</p></td><td><p>0.5</p></td><td><p>0.5</p></td><td><p>12</p></td><td colspan="6"><p>0</p></td><td><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Lymphopenia</p></td><td><p>42</p></td><td><p>9.7</p></td><td><p>0.5</p></td><td><p>25.8</p></td><td colspan="6"><p>5.3</p></td><td><p>0</p></td></tr><tr><td colspan="12"><p>Metabolism and nutrition disorders</p></td></tr><tr><td><p>Hypokalemia</p></td><td><p>17.9</p></td><td><p>1.9</p></td><td><p>0</p></td><td colspan="2"><p>2.4</p></td><td><p>0</p></td><td colspan="5"><p>0</p></td></tr><tr><td><p>Hypophosphatemia**</p></td><td><p>19.3</p></td><td><p>12.6</p></td><td><p>0</p></td><td colspan="2"><p>2.4</p></td><td><p>1.4</p></td><td colspan="5"><p>0</p></td></tr><tr><td colspan="12" style="vertical-align:top"><p>Hepatobiliary disorders</p></td></tr><tr><td style="vertical-align:top"><p>Bilirubin increased</p></td><td style="vertical-align:top"><p>8.7</p></td><td><p>0</p></td><td><p>0</p></td><td colspan="2"><p>4.8</p></td><td colspan="4" style="vertical-align:top"><p>0</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>ALT increased</p></td><td style="vertical-align:top"><p>58.9</p></td><td style="vertical-align:top"><p>3.4</p></td><td style="vertical-align:top"><p>1.0</p></td><td colspan="2"><p>24.4</p></td><td colspan="4" style="vertical-align:top"><p>0</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>AST increased</p></td><td style="vertical-align:top"><p>53.6</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>1.0</p></td><td colspan="2" style="vertical-align:top"><p>14.8</p></td><td colspan="4" style="vertical-align:top"><p>0</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="12" style="vertical-align:top"><p>Investigations</p></td></tr><tr><td style="vertical-align:top"><p>Amylase increased</p></td><td style="vertical-align:top"><p>12.6</p></td><td style="vertical-align:top"><p>2.4</p></td><td style="vertical-align:top"><p>1.4</p></td><td colspan="2" style="vertical-align:top"><p>6.2</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td><td colspan="4" style="vertical-align:top"><p>1.0</p></td></tr><tr><td style="vertical-align:top"><p>Lipase increased</p></td><td style="vertical-align:top"><p>11.1</p></td><td style="vertical-align:top"><p>2.4</p></td><td style="vertical-align:top"><p>0</p></td><td colspan="2" style="vertical-align:top"><p>2.9</p></td><td colspan="2" style="vertical-align:top"><p>0.5</p></td><td colspan="4" style="vertical-align:top"><p>0</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp; Common Terminology Criteria for Adverse Events (CTCAE), version 3.0</p><p>**&nbsp; The aetiology of hypophosphatemia associated with sorafenib is not known.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC).</p><p>SFDA call center: 19999.</p><p>Email: npc.drug@sfda.gov.sa.</p><p>Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment for sorafenib overdose. The highest dose of sorafenib studied clinically is 800&nbsp;mg twice daily. The adverse events observed at this dose were primarily diarrhoea and dermatological events. In the event of suspected overdose sorafenib should be withheld and supportive care instituted where necessary.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01EX02</p><p>&nbsp;</p><p>Sorafenib is a multikinase inhibitor which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo.</p><p>&nbsp;</p><p><u>Mechanism of action and pharmacodynamic effects</u></p><p><u>&nbsp;</u></p><p>Sorafenib is a multikinase inhibitor that decreases tumour cell proliferation <em>in vitro</em>. Sorafenib inhibits tumour growth of a broad spectrum of human tumour xenografts in athymic mice accompanied by a reduction of tumour angiogenesis. Sorafenib inhibits the activity of targets present in the tumour cell (CRAF, BRAF, V600E BRAF, c-KIT, and FLT-3) and in the tumour vasculature (CRAF, VEGFR-2, VEGFR-3, and PDGFR-&szlig;). RAF kinases are serine/threonine kinases, whereas<br />c-KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-&szlig; are receptor tyrosine kinases.</p><p>&nbsp;</p><p><u>Clinical efficacy</u></p><p><u>&nbsp;</u></p><p>The clinical safety and efficacy of sorafenib have been studied in patients with hepatocellular carcinoma (HCC), in patients with advanced renal cell carcinoma (RCC) and in patients with differentiated thyroid carcinoma (DTC).</p><p>&nbsp;</p><p><u>Hepatocellular carcinoma</u></p><p><u>&nbsp;</u></p><p>Study&nbsp;3 (study&nbsp;100554) was a Phase III, international, multi-centre, randomised, double blind, placebo-controlled study in 602 patients with hepatocellular carcinoma. Demographics and baseline disease characteristics were comparable between the sorafenib and the placebo group with regard to<s> </s>ECOG status (status 0:&nbsp;54&nbsp;% vs.&nbsp;54&nbsp;%; status 1:&nbsp;38&nbsp;% vs.&nbsp;39&nbsp;%; status 2:&nbsp;8&nbsp;% vs.&nbsp;7&nbsp;%), TNM stage (stage&nbsp;I:&nbsp;&lt;1&nbsp;% vs.&nbsp;&lt;1&nbsp;%; stage II:&nbsp;10.4&nbsp;% vs.&nbsp;8.3&nbsp;%; stage III:&nbsp;37.8&nbsp;% vs.&nbsp;43.6&nbsp;%; stage IV:&nbsp;50.8&nbsp;% vs.&nbsp;46.9&nbsp;%), and BCLC stage (stage B:&nbsp;18.1&nbsp;% vs.&nbsp;16.8&nbsp;%; stage C:&nbsp;81.6&nbsp;% vs.&nbsp;83.2&nbsp;%; stage D:&nbsp;&lt;&nbsp;1&nbsp;% vs.&nbsp;0&nbsp;%).</p><p>&nbsp;</p><p>The study was stopped after a planned interim analysis of OS had crossed the prespecified efficacy boundary. This OS analysis showed a statistically significant advantage for sorafenib over placebo for OS (HR:&nbsp;0.69, p&nbsp;=&nbsp;0.00058, see table&nbsp;3).</p><p>&nbsp;</p><p>There are limited data from this study in patients with Child Pugh B liver impairment and only one patient with Child Pugh C had been included.</p><p>&nbsp;</p><p><strong>Table 3: Efficacy results from study 3 (study 100554) in hepatocellular carcinoma</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Efficacy Parameter</p></td><td style="vertical-align:top"><p>Sorafenib</p><p>(N=299)</p></td><td style="vertical-align:top"><p>Placebo</p><p>(N=303)</p></td><td style="vertical-align:top"><p>P-value</p></td><td style="vertical-align:top"><p>HR</p><p>(95% CI)</p></td></tr><tr><td style="vertical-align:top"><p>Overall Survival (OS) [median, weeks (95% CI)]</p></td><td style="vertical-align:top"><p>46.3</p><p>(40.9, 57.9)</p></td><td style="vertical-align:top"><p>34.4</p><p>(29.4, 39.4)</p></td><td style="vertical-align:top"><p>0.00058*</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.69</p><p>(0.55, 0.87)</p></td></tr><tr><td style="vertical-align:top"><p>Time to Progression (TTP) [median, weeks (95% CI)]**</p></td><td style="vertical-align:top"><p>24.0</p><p>(18.0, 30.0)</p></td><td style="vertical-align:top"><p>12.3</p><p>(11.7, 17.1)</p></td><td style="vertical-align:top"><p>0.000007</p></td><td style="vertical-align:top"><p>0.58</p><p>(0.45, 0.74)</p></td></tr></tbody></table><p>CI=Confidence interval, HR=Hazard ratio (sorafenib over placebo)</p><p>*&nbsp;&nbsp;&nbsp;&nbsp; statistically significant as the p-value was below the prespecified O&rsquo;Brien Fleming stopping boundary of 0.0077</p><p>**&nbsp;&nbsp;&nbsp; independent radiological review</p><p>&nbsp;</p><p>A second Phase III, international, multi-centre, randomised, double blind, placebo-controlled study (Study 4, 11849) evaluated the clinical benefit of sorafenib in 226 patients with advanced hepatocellular carcinoma. This study, conducted in China, Korea and Taiwan confirmed the findings of Study 3 with respect to the favourable benefit-risk profile of sorafenib (HR (OS): 0.68, p&nbsp;=&nbsp;0.01414).</p><p>&nbsp;</p><p>In the pre-specified stratification factors (ECOG status, presence or absence of macroscopic vascular invasion and/or extrahepatic tumour spread) of both Study 3 and 4, the HR consistently favoured sorafenib over placebo. Exploratory subgroup analyses suggested that patients with distant metastases at baseline derived a less pronounced treatment effect.</p><p>&nbsp;</p><p><u>Renal cell carcinoma</u></p><p><u>&nbsp;</u></p><p>The safety and efficacy of sorafenib in the treatment of advanced renal cell carcinoma (RCC) were investigated in two clinical studies:</p><p>&nbsp;</p><p>Study&nbsp;1 (study&nbsp;11213) was a Phase III, multi-centre, randomised, double blind, placebo-controlled study in 903 patients. Only patients with clear cell renal carcinoma and low and intermediate risk MSKCC (Memorial Sloan Kettering Cancer Center) were included. The primary endpoints were overall survival and progression-free survival (PFS).</p><p>Approximately half of the patients had an ECOG performance status of 0, and half of the patients were in the low risk MSKCC prognostic group.</p><p>PFS was evaluated by blinded independent radiological review using RECIST criteria. The PFS analysis was conducted at 342 events in 769 patients. The median PFS was 167 days for patients randomised to sorafenib compared to 84 days for placebo patients (HR&nbsp;=&nbsp;0.44; 95&nbsp;% CI:&nbsp;0.35&nbsp;-&nbsp;0.55; p&nbsp;&lt;&nbsp;0.000001). Age, MSKCC prognostic group, ECOG PS and prior therapy did not affect the treatment effect size.</p><p>&nbsp;</p><p>An interim analysis (second interim analysis) for overall survival was conducted at 367 deaths in 903 patients. The nominal alpha value for this analysis was 0.0094. The median survival was 19.3 months for patients randomised to sorafenib compared to 15.9 months for placebo patients (HR&nbsp;=&nbsp;0.77; 95&nbsp;% CI: &nbsp;0.63&nbsp;-&nbsp;0.95; p&nbsp;=&nbsp;0.015). At the time of this analysis, about 200 patients had crossed-over to sorafenib from the placebo group.</p><p>&nbsp;</p><p>Study&nbsp;2 was a Phase&nbsp;II, discontinuation study in patients with metastatic malignancies, including RCC. Patients with stable disease on therapy with sorafenib were randomised to placebo or continued sorafenib therapy. Progression-free survival in patients with RCC was significantly longer in the sorafenib group (163 days) than in the placebo group (41 days) (p&nbsp;=&nbsp;0.0001, HR&nbsp;=&nbsp;0.29).</p><p>&nbsp;</p><p><u>Differentiated thyroid carcinoma (DTC)</u></p><p>&nbsp;</p><p>Study 5 (study 14295) was a Phase III, international, multi-centre, randomised, double blind, placebo-controlled trial in 417 patients with locally advanced or metastatic DTC refractory to radioactive iodine. Progression-free survival (PFS) as evaluated by a blinded independent radiological review using RECIST criteria was the primary endpoint of the study. Secondary endpoints included overall survival (OS), tumour response rate and duration of response. Following progression, patients were allowed to receive open label sorafenib.</p><p>Patients were included in the study if they experienced progression within 14 months of enrollment and had DTC refractory to radioactive iodine (RAI). DTC refractory to RAI was defined as having a lesion without iodine uptake on a RAI scan, or receiving cumulative RAI &ge; 22.2&nbsp; GBq, or experiencing a progression after a RAI treatment within 16 months of enrollment or after two RAI treatments within 16 months of each other.</p><p>&nbsp;</p><p>Baseline demographics and patient characteristics were well balanced for both treatment groups. Metastases were present in the lungs in 86%, lymph node in 51% and bone in 27% of the patients. The median delivered cumulative radioactive iodine activity before enrollment was approximately 14.8&nbsp; GBq. Majority of patients had papillary carcinoma (56.8%), followed by follicular (25.4%) and poorly differentiated carcinoma (9.6%).</p><p>&nbsp;</p><p>Median PFS time was 10.8 months in the sorafenib group compared to 5.8 months in the placebo group (HR=0.587; 95% Confidence Interval (CI): 0.454, 0.758; one-sided p &lt;0.0001).</p><p>The effect of sorafenib on PFS was consistent independent of geographic region, age above or below 60 years, gender, histological subtype, and presence or absence of bone metastasis.</p><p>&nbsp;</p><p>In an overall survival analysis conducted 9 months after the data cut-off for the final PFS analysis there was no statically significant difference in overall survival between the treatment groups (HR=0.884; 95% CI: 0.633, 1.236, one-sided p value of 0.236). The median OS was not reached in the&nbsp;sorafenib arm and was 36.5 months in the placebo arm. One hundred fifty seven (75%) patients randomised to placebo and 61 (30%) patients randomised to sorafenib received open-label sorafenib.</p><p>&nbsp;</p><p>The median duration of therapy in the double-blind period was 46 weeks (range 0.3-135) for patients receiving sorafenib and 28 weeks (range 1.7&ndash;132) for patients receiving placebo.</p><p>&nbsp;</p><p>No complete response (CR) according to RECIST was observed. The overall response rate (CR + partial response (PR) per independent radiological assessment was higher in the sorafenib group (24 patients, 12.2%) than in the placebo group (1 patient, 0.5%), one-sided p&lt;0.0001. The median duration of response was 309 days (95% CI: 226,505 days) in sorafenib treated patients who experienced a PR.</p><p>&nbsp;</p><p>A post-hoc subgroup analysis by maximum tumour size showed a treatment effect for PFS in favour of sorafenib over placebo for patients with maximum tumour size of 1.5 cm or larger (HR 0.54&nbsp; (95% CI: 0.41 - 0.71)) whereas a numerically lower effect was reported in patients with a maximum tumour size of less than 1.5 cm (HR 0.87 (95% CI: 0.40 - 1.89).</p><p>&nbsp;</p><p>A post-hoc subgroup analysis by thyroid carcinoma symptoms at baseline showed a treatment effect for PFS in favour of sorafenib over placebo for both symptomatic and asymptomatic patients. The HR of progression free survival was 0.39 (95% CI: 0.21 - 0.72) for patients with symptoms at baseline and 0.60 (95% CI: 0.45 - 0.81) for patients without symptoms at baseline.</p><p>&nbsp;</p><p><u>QT interval prolongation</u></p><p><u>&nbsp;</u></p><p>In a clinical pharmacology study, QT/QTc measurements were recorded in 31 patients at baseline (pre-treatment) and post-treatment. After one 28-day treatment cycle, at the time of maximum concentration of sorafenib, QTcB was prolonged by 4 &plusmn;19 msec and QTcF by 9 &plusmn;18 msec, as compared to placebo treatment at baseline. No subject showed a QTcB or QTcF &gt;500 msec during the post-treatment ECG monitoring (see section 4.4).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies, in all subsets of the paediatric population, in kidney and renal pelvis carcinoma (excluding nephroblastoma, nephroblastomatosis, clear cell sarcoma, mesoblastic nephroma, renal medullary carcinoma and rhabdoid tumour of the kidney) and liver and intrahepatic bile duct carcinoma (excluding hepatoblastoma) and differentiated thyroid carcinoma (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption and distribution</u></p><p>&nbsp;</p><p>After administration of sorafenib tablets the mean relative bioavailability is 38&nbsp;-&nbsp;49&nbsp;% when compared to an oral solution. The absolute bioavailability is not known. Following oral administration sorafenib reaches peak plasma concentrations in approximately 3 hours. When given with a high-fat meal sorafenib absorption was reduced by 30&nbsp;% compared to administration in the fasted state.</p><p>Mean C<sub>max</sub> and AUC increased less than proportionally beyond doses of 400&nbsp;mg administered twice daily. <em>In vitro</em> binding of sorafenib to human plasma proteins is 99.5&nbsp;%.</p><p>Multiple dosing of sorafenib for 7 days resulted in a 2.5- to 7-fold accumulation compared to single dose administration. Steady state plasma sorafenib concentrations are achieved within 7 days, with a peak to trough ratio of mean concentrations of less than 2.</p><p>&nbsp;</p><p>The steady-state concentrations of sorafenib administered at 400 mg twice daily were evaluated in DTC, RCC and HCC patients. The highest mean concentration was observed in DTC patients (approximately twice that observed in patients with RCC and HCC), though variability was high for all tumour types. The reason for the increased concentration in DTC patients is unknown.</p><p>&nbsp;</p><p><u>Biotransformation and elimination</u></p><p><u>&nbsp;</u></p><p>The elimination half-life of sorafenib is approximately 25&nbsp;-&nbsp;48 hours. Sorafenib is metabolised primarily in the liver and undergoes oxidative metabolism, mediated by CYP 3A4, as well as glucuronidation mediated by UGT1A9. Sorafenib conjugates may be cleaved in the gastrointestinal tract by bacterial glucuronidase activity, allowing reabsorption of unconjugated active substance. Co-administration of neomycin has been shown to interfere with this process, decreasing the mean bioavailability of sorafenib by 54%.</p><p>&nbsp;</p><p>Sorafenib accounts for approximately 70&nbsp;-&nbsp;85&nbsp;% of the circulating analytes in plasma at steady state. Eight metabolites of sorafenib have been identified, of which five have been detected in plasma. The main circulating metabolite of sorafenib in plasma, the pyridine N-oxide, shows <em>in vitro</em> potency similar to that of sorafenib. This metabolite comprises approximately 9&nbsp;-&nbsp;16&nbsp;% of circulating analytes at steady state.</p><p>&nbsp;</p><p>Following oral administration of a 100&nbsp;mg dose of a solution formulation of sorafenib, 96&nbsp;% of the dose was recovered within 14 days, with 77&nbsp;% of the dose excreted in faeces, and 19&nbsp;% of the dose excreted in urine as glucuronidated metabolites. Unchanged sorafenib, accounting for 51&nbsp;% of the dose, was found in faeces but not in urine, indicating that biliary excretion of unchanged active substance might contribute to the elimination of sorafenib.</p><p>&nbsp;</p><p><u>Pharmacokinetics in special populations</u></p><p><u>&nbsp;</u></p><p>Analyses of demographic data suggest that there is no relationship between pharmacokinetics and age (up to 65 years), gender or body weight.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>No studies have been conducted to investigate the pharmacokinetics of sorafenib in paediatric patients.</p><p>&nbsp;</p><p><u>Race</u></p><p><u>&nbsp;</u></p><p>There are no clinically relevant differences in pharmacokinetics between Caucasian and Asian subjects.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p><u>&nbsp;</u></p><p>In four Phase&nbsp;I clinical trials, steady state exposure to sorafenib was similar in patients with mild or moderate renal impairment compared to the exposures in patients with normal renal function. In a clinical pharmacology study (single dose of 400&nbsp;mg sorafenib), no relationship was observed between sorafenib exposure and renal function in subjects with normal renal function, mild, moderate or severe renal impairment. No data is available in patients requiring dialysis.</p><p><em>&nbsp;</em></p><p><u>Hepatic impairment</u></p><p><u>&nbsp;</u></p><p>In hepatocellular carcinoma <em>(HCC)</em> patients with Child-Pugh A or B (mild to moderate) hepatic impairment, exposure values were comparable and within the range observed in patients without hepatic impairment. The pharmacokinetics (PK) of sorafenib in Child-Pugh A and B non&shy;-HCC patients were similar to the PK in healthy volunteers. There are no data for patients with Child-Pugh C (severe) hepatic impairment. Sorafenib is mainly eliminated via the liver, and exposure might be increased in this patient population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The preclinical safety profile of sorafenib was assessed in mice, rats, dogs and rabbits.</p><p>Repeat-dose toxicity studies revealed changes (degenerations and regenerations) in various organs at exposures below the anticipated clinical exposure (based on AUC comparisons).</p><p>After repeated dosing to young and growing dogs effects on bone and teeth were observed at exposures below the clinical exposure. Changes consisted in irregular thickening of the femoral growth plate, hypocellularity of the bone marrow next to the altered growth plate and alterations of the dentin composition. Similar effects were not induced in adult dogs.</p><p>&nbsp;</p><p>The standard program of genotoxicity studies was conducted and positive results were obtained as an increase in structural chromosomal aberrations in an <em>in vitro</em> mammalian cell assay (Chinese hamster ovary) for clastogenicity in the presence of metabolic activation was seen. Sorafenib was not genotoxic in the Ames test or in the <em>in vivo</em> mouse micronucleus assay. One intermediate in the manufacturing process, which is also present in the final active substance (&lt;&nbsp;0.15&nbsp;%), was positive for mutagenesis in an <em>in vitro</em> bacterial cell assay (Ames test). Furthermore, the sorafenib batch tested in the standard genotoxicity battery included 0.34&nbsp;% PAPE.</p><p>Carcinogenicity studies have not been conducted with sorafenib.</p><p>&nbsp;</p><p>No specific studies with sorafenib have been conducted in animals to evaluate the effect on fertility. An adverse effect on male and female fertility can however be expected because repeat-dose studies in animals have shown changes in male and female reproductive organs at exposures below the anticipated clinical exposure (based on AUC). Typical changes consisted of signs of degeneration and retardation in testes, epididymides, prostate, and seminal vesicles of rats. Female rats showed central necrosis of the corpora lutea and arrested follicular development in the ovaries. Dogs showed tubular degeneration in the testes and oligospermia.</p><p>&nbsp;</p><p>Sorafenib has been shown to be embryotoxic and teratogenic when administered to rats and rabbits at exposures below the clinical exposure. Observed effects included decreases in maternal and foetal body weights, an increased number of foetal resorptions and an increased number of external and visceral malformations.</p><p>&nbsp;</p><p>Environmental Risk assessment studies have shown that sorafenib tosylate has the potential to be persistent, bioaccumulative and toxic to the environment. Environmental Risk Assessment information is available in the EPAR of this medicine (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core:</u></p><p>Croscarmellose sodium</p><p>Microcrystalline cellulose</p><p>Hypromellose</p><p>Sodium laurilsulfate</p><p>Magnesium stearate</p><p>&nbsp;</p><p><u>Tablet coating:</u></p><p>Hypromellose</p><p>Macrogol (3350)</p><p>Titanium dioxide (E 171)</p><p>Ferric oxide red (E 172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>60 film-coated tablets (6 x 10) in Alu/Alu blister packs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product could have potential risk for the environment. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><u>Handling:</u></p><p>&bull;&nbsp; Nexavar is a Hazardous drug, as it may cause reproductive toxicity.</p><p>&bull;&nbsp; Women who are pregnant or who may be pregnant should not handle Nexavar crushed or broken coated tablets.</p><p>&bull;&nbsp; To minimize the risk of dermal exposure, wear gloves when handling<em> NEXAVAR.</em></p><p>&bull;&nbsp; The tablets should not be divided, broken or crushed. This might produce powder that can contaminate workplace surfaces.</p><p>&bull;&nbsp; Caution should be observed in handling broken or crushed tablets; wear double chemotherapy gloves and place in double bag or in a sealed container. Avoid direct contact with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, rinse eyes thoroughly with sterile water, or plain water if sterile water is unavailable.</p><p>&bull;&nbsp; When manipulations are necessary such as compounding, crushing, cutting, or splitting; recommended to wear double gloves, and be performed within a ventilated engineering enclosure and/ or augment the control of generated aerosols using supplementary controls such as glove bags or pill pouches that contain the hazardous drug during and after the crushing process.</p><p>&bull;&nbsp; For medication administration, wear single gloves with intact and coated tablets and double gloves with cut or crushed tablets. Add eye and face protection if there is the potential to contact vomit or if patient may resist or is pre-disposed to spitting out</p><p><u>&nbsp;</u></p><p><u>Disposal: </u></p><p>Wear gloves and protective gown for any disposal or cleaning activity of medication contaminated waste.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bayer AG
51368 Leverkusen
Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>